

A Novel Triple-Targeting Bispecific Fusion Protein

Drug Name	***0153
Description	A bispecific fusion protein consisting of the extracellular domain of CD80 fused to a bivalent IL-2 variant is developed for the treatment of solid tumors. The product elicited the restoration of immune functions to enhance the anti-tumor effect.
Target	CTLA4; IL-2; PD-L1
Drug Modality	Fusion Protein
Indication	Solid Tumor
Product Category	Cancer Immunotherapy
Mechanism of Action	Inhibiting the immune checkpoint to enhance the activation of immune cells
Status	Preclinical
Patent	Granted

More Detail Available Upon Request

We look forward to hearing from you.